The insulin‐like growth factor binding protein‐3 and its death receptor in pancreatic ductal adenocarcinoma poor prognosis

2019 ◽  
Vol 234 (12) ◽  
pp. 23537-23546 ◽  
Author(s):  
Ali Gheysarzadeh ◽  
Hadi Bakhtiari ◽  
Amir Ansari ◽  
Amirnader Emami Razavi ◽  
Mohammad H. Emami ◽  
...  
Keyword(s):  
Growth Factor ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Poor Prognosis ◽  
Binding Protein ◽  
Death Receptor ◽  
Ductal Adenocarcinoma ◽  
Insulin Like Growth Factor ◽  
Factor Binding

Insulin-like growth factor 2 mRNA binding protein 2 promotes aerobic glycolysis and cell proliferation in pancreatic ductal adenocarcinoma via stabilizing GLUT1 mRNA

2019 ◽  
Vol 51 (7) ◽  
pp. 743-752 ◽  
Author(s):  
Shan Huang ◽  
Zheng Wu ◽  
Yunyun Cheng ◽  
Wenzhen Wei ◽  
Linlin Hao
Keyword(s):  
Cell Proliferation ◽  
Growth Factor ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Binding Protein ◽  
Aerobic Glycolysis ◽  
Ductal Adenocarcinoma ◽  
Insulin Like Growth Factor ◽  
Mrna Binding Protein ◽  
Mrna Binding ◽  
Glut1 Mrna

Abstract Insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2) is a member of the IGF2BP protein family consisting of IGF2BP1~3 with the capacity of binding to many transcripts and regulating RNA stability, localization, and translation. In this study, we discovered that expression of IGF2BP2 was upregulated and led to a poor prognosis in pancreatic ductal adenocarcinoma (PDAC). IGF2BP2 protein was gradually elevated from normal pancreas, pancreatic intraepithelial neoplasia to PDAC in an LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx1-Cre mouse model. Furthermore, we demonstrated that IGF2BP2 promoted aerobic glycolysis and PDAC cell proliferation through directly binding to and stabilizing GLUT1 mRNA. In summary, our study unveiled an important role of IGF2BP2 in PDAC development by modulating aerobic glycolysis and as a potential therapeutic target for PDAC treatment.

Sign in / Sign up

Export Citation Format

Share Document